Literature DB >> 14986557

Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting.

Jared T Lurk1, Douglas J DeJong, T Mark Woods, Maureen E Knell, Cathryn A Carroll.   

Abstract

PURPOSE: The impact of cost-containment strategies on prescription drug utilization and costs in an ambulatory care safety-net-provider setting was studied, along with the impact of these strategies on patient out-of-pocket expenditures.
METHODS: Aggregate monthly prescription drug cost and utilization data were obtained from a health system's outpatient pharmacy computer system for the targeted clinic. The data represented approximately 42,000 patient visits over 38 months. Univariate and multivariate statistics were used to evaluate the influence of copayment increases and changes in prescription drug sample policies on prescription drug costs, prescription drug utilization, and patient expenditures.
RESULTS: Prescription drug copayment increases were associated with significant decreases in prescription drug utilization and costs. An average per visit prescription drug copayment increase of $5 was associated with a significant reduction in prescription drug utilization per visit and a $26.07 reduction in prescription drug expenditures per visit per month. Removal of samples from the clinic did not result in a significant decrease in either prescription drug costs or utilization. The presence of samples, however, was associated with a significant reduction in per visit patient expenditures by an amount similar to the copayment for one brand-name prescription drug per visit.
CONCLUSION: An increase in patient copayments was associated with reductions in a clinic's drug expenditures and prescription drug utilization per visit. Removal of prescription drug samples had no effect except increasing patients' out-of-pocket drug costs.

Entities:  

Mesh:

Year:  2004        PMID: 14986557     DOI: 10.1093/ajhp/61.3.267

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

1.  Modeling the potential impact of a prescription drug copayment increase on the adult asthmatic medicaid population.

Authors:  Seung Jin Bae; A David Paltiel; Anne L Fuhlbrigge; Scott T Weiss; Karen M Kuntz
Journal:  Value Health       Date:  2008 Jan-Feb       Impact factor: 5.725

2.  An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis.

Authors:  L Caplan; A E Hines; E Williams; A V Prochazka; K G Saag; F Cunningham; E Hutt
Journal:  Osteoporos Int       Date:  2010-04-01       Impact factor: 4.507

3.  Drug samples in family medicine teaching units: a cross-sectional descriptive study: Part 2: portrait of drug sample management in Quebec.

Authors:  Andréa Lessard; Marie-Thérèse Lussier; Fatoumata Binta Diallo; Michel Labrecque; Caroline Rhéaume; Pierre Pluye; Roland Grad
Journal:  Can Fam Physician       Date:  2018-12       Impact factor: 3.275

Review 4.  Systematic review on quality control for drug management programs: is quality reported in the literature?

Authors:  Anke-Peggy Holtorf; Carrie McAdam-Marx; David Schaaf; Benjamin Eng; Gary Oderda
Journal:  BMC Health Serv Res       Date:  2009-02-25       Impact factor: 2.655

5.  What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.

Authors:  Marin C Gemmill; Sarah Thomson; Elias Mossialos
Journal:  Int J Equity Health       Date:  2008-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.